Home Cart Sign in  
Chemical Structure| 471905-41-6 Chemical Structure| 471905-41-6

Structure of MK-0752
CAS No.: 471905-41-6

Chemical Structure| 471905-41-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MK-0752 is a moderately potent γ-secretase inhibitor, which reduces Aβ40 production with IC50 of 5 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MK-0752

CAS No. :471905-41-6
Formula : C21H21ClF2O4S
M.W : 442.90
SMILES Code : O=C(O)CC[C@H]1CC[C@](C2=CC(F)=CC=C2F)(S(=O)(C3=CC=C(Cl)C=C3)=O)CC1
MDL No. :MFCD21608529
InChI Key :XCGJIFAKUZNNOR-UHFFFAOYSA-N
Pubchem ID :9803433

Safety of MK-0752

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SK-UT-1B and SK-LMS-1 50-95 µM 24 h to determine the effects of MK-0752 on Notch signaling and cell viability; significant decrease in expression of HES1 and increased death of uLMS cells PMC9180633
SK-LMS-1 50-100 µM 24 h to determine the effects of MK-0752 on Notch signaling and cell viability; significant decrease in expression of HES1 and increased death of uLMS cells PMC9180633
H4 cells 4 pM to 10 µM overnight To evaluate the inhibitory effects of MK-0752 on cNOTCH1-4 and cAPPC100 substrates, results showed that MK-0752 equivalently inhibited cleavage of cNOTCH1, 2, and 4, but increased cleavage of cNOTCH3 at low doses. PMC5494507
MDA-MB-231 cells 0.1 µM to 12.5 µM 1 hour To evaluate the inhibitory effects of MK-0752 on endogenous NOTCH1 cleavage, results showed that MK-0752 significantly reduced NICD levels at concentrations ≥0.5 µM. PMC5494507
SK-UT-1B cells 40.2 µM 72 hours To evaluate the synergistic effects of MK-0752 with chemotherapeutic agents, results showed that MK-0752 was synergistic with doxorubicin and gemcitabine plus docetaxel in SK-UT-1B cells. PMC11201464
SK-LMS-1 cells 135 µM 72 hours To evaluate the synergistic effects of MK-0752 with chemotherapeutic agents, results showed that MK-0752 was synergistic with all individual agents and with the combination of gemcitabine plus docetaxel in SK-LMS-1 cells. PMC11201464
A375 cells 50 μM and 100 μM 48 hours MK-0752 treatment significantly reduced the viability and growth of A375 cells, and showed synergistic anti-proliferative effects when combined with BI 6727. PMC7790869
SK-MEL-2 cells 50 μM and 100 μM 48 hours MK-0752 treatment significantly reduced the viability and growth of SK-MEL-2 cells, and showed synergistic anti-proliferative effects when combined with BI 6727. PMC7790869
SK-MEL-28 cells 50 μM and 100 μM 48 hours MK-0752 treatment significantly reduced the viability and growth of SK-MEL-28 cells, and showed synergistic anti-proliferative effects when combined with BI 6727. PMC7790869
MMECs 5 nM 48 hours MK-0752 significantly reduced MMECs’ spontaneous migration, chemotaxis, adhesion, and Matrigel angiogenesis. PMC6282459
SUM149 cells 25 μM 7 days MK-0752 treatment significantly upregulated the expression of stem cell genes Nanog, Sox2, Oct4 in cancer cells and increased mammosphere formation, thus indicating that MK-0752 treatment might enrich breast cancer stem cells in breast cancer cell lines. PMC5762847
MCF-7 cells 25 μM 7 days MK-0752 treatment significantly upregulated the expression of stem cell genes Nanog, Sox2, Oct4 in cancer cells and increased mammosphere formation, thus indicating that MK-0752 treatment might enrich breast cancer stem cells in breast cancer cell lines. PMC5762847
HCC1954 cells 25 μM 7 days MK-0752 treatment significantly upregulated the expression of stem cell genes Nanog, Sox2, Oct4 in cancer cells and increased mammosphere formation, thus indicating that MK-0752 treatment might enrich breast cancer stem cells in breast cancer cell lines. PMC5762847

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
rhesus monkeys CNS-penetrant model Oral 240 mg/kg single dose during the stability study To evaluate the effects of MK-0752 on CNS Aβ production, showing a dose-dependent reduction without rebound effects. PMC2913973
C57BL/6J mice Vk12598/C57BL/6J mouse model Intraperitoneal injection 5 mg/kg Every 3 days for 5 weeks MK-0752 restrained angiogenesis by reducing microvessel density and CD31-positive ECs, and it also reduced tumor burden. PMC6282459
Nude mice Breast cancer cell line SUM149 xenograft model Oral 25 mg/kg Twice a week, until the end of treatment The combination of MK-0752 and Tocilizumab significantly inhibited tumor growth and reduced the CD24?CD44+ breast cancer stem cell population, indicating that the IL6R antagonist Tocilizumab enhances the anti-tumor efficacy of MK-0752 by blocking the IL6-dependent increase in breast cancer stem cells. PMC5762847

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.26mL

0.45mL

0.23mL

11.29mL

2.26mL

1.13mL

22.58mL

4.52mL

2.26mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories